Last reviewed · How we verify
optimised rituximab-schedule
Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells.
Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells. Used for Non-Hodgkin lymphoma, Rheumatoid arthritis.
At a glance
| Generic name | optimised rituximab-schedule |
|---|---|
| Sponsor | Universität des Saarlandes |
| Drug class | Monoclonal antibody |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology, Immunology |
| Phase | Phase 3 |
Mechanism of action
By binding to the CD20 antigen on the surface of B cells, rituximab triggers cell-mediated cytotoxicity and induces apoptosis, leading to a reduction in B cell count and activity. This mechanism is particularly effective in treating B cell-related disorders such as non-Hodgkin lymphoma and rheumatoid arthritis.
Approved indications
- Non-Hodgkin lymphoma
- Rheumatoid arthritis
Common side effects
- Infusion-related reactions
- Infections
- Neutropenia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- optimised rituximab-schedule CI brief — competitive landscape report
- optimised rituximab-schedule updates RSS · CI watch RSS
- Universität des Saarlandes portfolio CI